Title:
MOLECULE, CELL EXPRESSING THE SAME, AND PREPARATION METHOD AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2017/219916
Kind Code:
A1
Abstract:
Provided are a chimeric immune inhibitory checkpoint receptor molecule, a nucleic acid encoding the same, a construct, expression vector and transformed cell containing the nucleic acid, and a pharmaceutical use thereof. The chimeric immune inhibitory checkpoint receptor molecule comprises an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain and the optional transmembrane domain are corresponding domains of an immune inhibitory checkpoint receptor molecule or are genetically engineered on the basis of the corresponding domains. The intracellular domain is one or more immune activation signal domains. The transformed cell has a strong tumor-killing effect and can abrogate a tumor-immunosuppressive microenvironment, thereby strengthening an immune response in the tumor microenvironment. The transformed cell also has a self-regulation function and can alleviate side effects such as an overactive, non-specific immune response and a cytokine storm.
Inventors:
LI PENG (CN)
WEI XINRU (CN)
YE WEI (CN)
ZHAO RUOCONG (CN)
LAI YUNXIN (CN)
LIN SIMIAO (CN)
YAO YAO (CN)
WEI XINRU (CN)
YE WEI (CN)
ZHAO RUOCONG (CN)
LAI YUNXIN (CN)
LIN SIMIAO (CN)
YAO YAO (CN)
Application Number:
PCT/CN2017/088594
Publication Date:
December 28, 2017
Filing Date:
June 16, 2017
Export Citation:
Assignee:
SHENZHEN IN VIVO BIOMEDICINE TECH LIMITED COMPANY (CN)
International Classes:
A61K38/17; A61P35/00; C07K19/00
Domestic Patent References:
| WO2015112626A1 | 2015-07-30 | |||
| WO2014031687A1 | 2014-02-27 | |||
| WO2015095895A1 | 2015-06-25 |
Foreign References:
| CN105153315A | 2015-12-16 | |||
| CN103965361A | 2014-08-06 | |||
| CN105601752A | 2016-05-25 | |||
| CN104829733A | 2015-08-12 | |||
| CN105331585A | 2016-02-17 |
Attorney, Agent or Firm:
BEYOND ATTORNEYS AT LAW (CN)
Download PDF: